The National Medical Products Administration (NMPA) recently accepted the investigational new drug (IND) application of HP530S tablets, a Hinova self-developed FAK inhibitor for clinical trial on solid tumors.

HP530S tablet is a highly active and selective Focal adhesion kinase (FAK) inhibitor discovered and developed by the company. It is a first in class new drug. HP530S regulates FAK downstream signaling pathways by inhibiting FAK, thus inhibiting tumor cell metastasis, proliferation and angiogenesis.

Focal adhesion kinase (FAK) is a ubiquitous intracellular non-receptor tyrosine kinase, and a key regulator in integrin-mediated signaling pathways. FAK over expression has been reported in multiple tumor types, including ovarian, breast, lung, colorectal, pancreatic, prostate, and head and neck cancers. Such overexpression is often associated with poor clinical prognosis. In contrast, it has been demonstrated that inhibition or degradation of FAK could inhibit the proliferation, migration and survival of tumor cells.

Current treatment options for solid tumors are associated with post-treatment drug resistance, immune escape and safety risks. With increasing morbidity and mortality of malignant tumors, especially solid tumors, better treatment options are in demand. Therefore, the development of new safe and efficacious drugs for the treatment of solid tumors will help to address unmet clinical needs.

HP530S showed inhibition of proliferation and migration of tumor cells. In preclinical toxicology studies, HP530S turned out to be safe. HP530S also demonstrated excellent potential for combination therapies. 

Dr. Yuanwei Chen, President and CEO of Hinova, stated: "When it comes to malignant tumors, there are numerous unmet medical needs. In light of this, we will further investigate into the broad-spectrum anti-tumor potential of HP530S to develop an innovative drug that offers an efficacious and safe treatment option to more patients!”

About Hinova

Hinova is an international and clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases. Hinova has committed to the discovery and development of innovative medicines for patients globally through deuteration and targeted protein degradation technologies.